Rapport Therapeutics, Inc.
RAPP
$38.08
$0.842.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -34.60% | -42.37% | -35.99% | -40.14% | -55.34% |
| Total Depreciation and Amortization | 7.41% | 21.22% | 60.13% | 123.62% | 273.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.14% | 29.46% | 48.39% | 18.69% | -1.21% |
| Change in Net Operating Assets | 929.22% | 244.95% | 168.17% | -410.02% | 471.08% |
| Cash from Operations | -19.05% | -34.93% | -27.13% | -53.11% | -68.65% |
| Capital Expenditure | 74.69% | 74.39% | 81.39% | 80.75% | 38.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -61.19% | -11.40% | 107.02% | 110.34% | 10.60% |
| Cash from Investing | -59.13% | -10.19% | 106.69% | 109.89% | 11.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 70.69% | 70.19% | 70.01% | -99.99% | 530,273.33% |
| Repurchase of Common Stock | 99.64% | 99.93% | 99.93% | -34,775.00% | -34,775.00% |
| Issuance of Preferred Stock | -- | -- | -100.00% | -100.00% | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 66.28% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -196.47% | -- | 100.00% | 17.11% | 170.93% |
| Cash from Financing | 71.75% | 22.18% | 22.13% | -100.47% | 6.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 222.74% | 68.82% | 276.71% | -279.23% | -39.66% |